Infliximab is :
**Core Concept**
Infliximab is a medication used to treat various autoimmune diseases by targeting a specific component of the immune system. It is a **chimeric monoclonal antibody** that plays a crucial role in **immunomodulation**. Infliximab's mechanism involves binding to a key pro-inflammatory cytokine.
**Why the Correct Answer is Right**
Infliximab works by binding to **tumor necrosis factor-alpha (TNF-alpha)**, a pro-inflammatory cytokine involved in systemic inflammation and a key player in the pathogenesis of several autoimmune diseases. By inhibiting TNF-alpha, infliximab reduces inflammation and halts disease progression in conditions like **rheumatoid arthritis**, **Crohn's disease**, and **psoriasis**. This targeted therapy has significantly improved the management of these chronic diseases.
**Why Each Wrong Option is Incorrect**
**Option A:** Incorrect because it does not specify the mechanism or target of infliximab.
**Option B:** Incorrect as it does not relate to the function or class of infliximab.
**Option C:** Incorrect because, although it might be related to immunology, it does not accurately describe infliximab.
**Clinical Pearl / High-Yield Fact**
A key point to remember is that infliximab, being a **chimeric antibody**, has a higher risk of inducing **antibody formation against itself** compared to fully humanized antibodies, which can lead to reduced efficacy over time. Monitoring for **loss of response** and considering **dose escalation** or **switching to another agent** are important clinical strategies.
**Correct Answer:** D. A chimeric monoclonal antibody against TNF-alpha.